[REVISION HISTORY]

China biopharmaceutical industry growth

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-19 16:19 UTC → 2026-09-29 14:43 UTC · added ~~removed~~

China is expanding its national health insurance coverage to include more innovative drugs, specifically targeting cancer, chronic, rare, and pediatric conditions. Since 2018, the National Healthcare Security Administration has added 949 medicines to the national insurance list, including 199 innovative drugs. ~~Authorities also aim to shorten approval times and encourage private insurance coverage for clinically significant drugs.~~ This domestic policy support coincides with China’s emergence as a dominant force in the global biopharmaceutical ~~ecosystem. China has~~ ecosystem, having become the world’s second-largest developer of innovative ~~drugs, utilizing faster and more cost-effective clinical trials. The scale of this growth is evidenced by the value of Chinese out-licensing deals, which reached $115 billion in 2025.~~ drugs. To ~~accelerate~~ solidify this ~~trajectory,~~ position, ten government ~~agencies, including the Ministry of Industry and Information Technology,~~ agencies have unveiled a strategic five-year plan for ~~2026–2030~~ 2026–2030. This plan aims to transform the sector into a global biomedical ~~powerhouse. The plan targets~~ powerhouse by targeting an annual growth rate of over 20% for innovative ~~medicine and aims~~ medicine. A primary objective is for ‘first-in-class’ drugs to account for more than 25% of the global market by 2030. ~~Specific goals include developing~~ The roadmap also seeks to develop at least five Chinese drugs with annual global sales exceeding one billion dollars and ~~driving~~ drive total revenues for major pharmaceutical companies to at least 3.5 trillion ~~yuan by 2030.~~ yuan. The ~~roadmap~~ strategy emphasizes high-tech fields such as gene editing, cell therapies, regenerative medicine, and artificial intelligence in drug discovery. To support this, the plan mandates that average R&D investment for listed pharmaceutical companies must exceed 10% of their revenue and seeks to approve more than 200 innovative medical devices. ~~While China’s influence reshapes global dealmaking, its rise has sparked debate~~ Additionally, the industry is transitioning toward a high-quality development model focused on health outcomes and original innovation. This includes growth in the ~~United States regarding national security~~ medicine and ~~research funding.~~ food homology sector, which is projected to exceed RMB 450 billion, driven by shifting consumer demand toward proactive wellness among Generation Z and the ‘new silver generation’.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.